ALLIANCE FOR CANCER GENE THERAPY

is the only charitable organization in the nation dedicated exclusively
to funding and fostering research into molecular medicine for cancers.

OUR MISSION is to seek out and support revolutionary scientific
research into the causes, treatment and prevention of all types of
cancer using cell and genes as medicine.

TO THIS END we fund and monitor studies and trials that meet the
highest possible standards, educate the public on the potential, and
facilitate greater collaboration among the scientific and philanthropic
communities to promote progress.
My husband Edward and I founded Alliance for Cancer Gene Therapy because we had come to believe, and I believe even more fervently now, that cell and gene therapies will be the breakthrough that so many of us seek to end cancer as we know it.

Many of our Research Fellows published landmark studies this year:

- Dr. Khalid Shah at Harvard Medical School reported progress identifying stem cell lines that respond to oncolytic virus therapy for brain cancer (glioblastoma).
- Dr. Yiping Yang at Duke University confirmed signals between tumors and the immune system in his quest for a vaccine against lymphoma and leukemia.
- Dr. Michel Sadelain at Memorial Sloan-Kettering Cancer Center has successfully deployed the immune system to destroy tumors, with fewer side effects; and because the cells stay in the body they are ‘living drugs’ to prevent recurrences.
- One of our 2012 grant recipients, Dr. Herbert J. Zeh, III, University of Pittsburgh Medical Center, launched a trial deploying a combination of immunotherapy and targeted vaccine therapy for pancreatic and colorectal cancers, among the most deadly.
- And, Dr. Carl June’s breakthrough research at the University of Pennsylvania is proving again and again to be at the forefront of immunotherapy for cancers of all types.

The molecular medicine that underscores the research is proving again and again to effectively treat all forms of cancer, on its own or in conjunction with other treatments, resulting in sustained remissions or in the total annihilation of tumors.

To all who support our cause, thank you. I assure you that our dedicated team is doing all we can to advance the progress of molecular medicine, hopefully before you or someone you care about hears these words: you have cancer.

Barbara Netter, President and Co-Founder
Alliance for Cancer Gene Therapy
An immunotherapy cure was first reported in Paris in 2000, followed by comparable results in other European medical centers.

Lung cancer patients treated six years ago with a gene therapy drug at the M.D. Anderson Cancer Center in Texas are alive and well, and in 20 clinical studies using the drug on eight different types of cancer, there were minimal side effects.

Laboratory researchers at Columbia University Medical Center are using virus-infused cancer cells to eradicate prostate cancer in animals, with no damage to other cells in the body.

A 42-year old Pennsylvania woman with brain cancer was among the first to receive cancer gene therapy in 2000 - she continues to enjoy good health.

Five years ago, a lung-cancer patient, whose previous treatments failed to halt the disease, participated in a trial at the University of Miami using a gene therapy vaccine that boosts the impact of chemotherapy - she had no side effects and she is still in remission.

A 7-year old girl dying of leukemia is cancer free because of a clinical trial at the University of Pennsylvania - using her own cancer cells, researchers trained her immune system to fight back. The trial was based on research first funded by ACGT.

A team of researchers at Memorial Sloan-Kettering Cancer Center developed a method for mass-producing cells programmed to target and destroy lymphoma/leukemia cells, and remain in the body to defend against recurrence.
Someone you know or someone you love will be diagnosed with cancer this year and someone you know or someone you love might die of cancer some time soon.

Yet the treatments have hardly changed in fifty years and treatments can be nearly as debilitating as the disease.

...WHILE TRADITIONAL TREATMENTS DON’T DO ENOUGH

Someone you know or someone you love will be diagnosed with cancer this year and someone you know or someone you love might die of cancer some time soon.

Yet the treatments have hardly changed in fifty years and treatments can be nearly as debilitating as the disease.

1 of 4 Americans will develop cancer at some point in time

2 people will discover they have cancer every minute of every day

NEARLY 1,600 CANCER DEATHS PER YEAR

Almost 1,600 Americans die of cancer-related deaths and, during ages 45 – 64, cancer is responsible for more deaths than the next three most common causes combined

7 MILLION

7 million people around the world will perish from cancer this year

Source: American Cancer Society
Research into molecular medicine is progressing rapidly toward a new way of understanding and treating cancers of all types and good research needs support to accelerate the momentum from the lab to medical practice.

Funding for innovative research in the laboratory is very hard to come by, especially with reduced government spending and economic pressures on private capital.

- The NIH spends very little on discovery research.
- Biotechnology firms take on few studies at a time.
- Pharmaceutical companies invest primarily in projects with proven market potential.

ACGT funds groundbreaking research by the best-trained research scientists in the country, although too many go unfunded because of limited resources.

ACGT equally funds translational research, where successful laboratory studies proceed to human trials for further testing – these trials also save lives.

ACGT Research Fellows have often received matching or translational funding based on successful research studies funded first by ACGT.

Barbara Netter
President & Co-Founder
Alliance for Cancer Gene Therapy

It is important to note that there has been significant overall progress in recent years against cancer, based largely on early detection and more aggressive treatments, and 5-year survival rates have improved. However, 11 million Americans live with the threat of a second bout of cancer and more than half a million men, women and children, every year, will receive the horrible news that they too must do battle.
Molecular medicine uses the body’s own cells and genes as both the source and the medicine for many diseases.

This field of study explains the fundamental genetic errors that cause diseases like cancer, as well as creating a blueprint for good health.

Advances in technology make it possible to directly target cancers without damage to other parts of the body, thus with few, if any, side effects.

Molecular medicine is the bridge between traditional medical practice and our rapidly growing ability to zero in on the precise and individualized causes of cancer and treatment.

Molecular medicine is also referred to as genetic medicine, gene therapy, targeted therapeutics, genetic epidemiology, precision medicine, or individualized medicine.
THE SCIENCE IS THE RESULT OF
CENTURIES OF SCIENTIFIC DISCOVERY

1500’s
DaVinci’s drawings of human anatomy

1600’s
Physics & Chemistry explained

1700’s
Diphtheria, Pertussis, TB, Tetanus, Yellow Fever Vaccines
Inoculation against Measles, Mumps, Rubella, Hepatitis B, Polio
Identification of DNA as the genetic code

1800’s
Identification of DNA as the genetic code

1900’s
Successful transfer of gene into a mouse

1966
Columbia University Symposium on possibility of gene therapy

1985
1st human gene transfer trial

1989

ALLIANCE FOR CANCER GENE THERAPY
<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>First gene therapy cure reported in Paris</td>
</tr>
<tr>
<td>2001</td>
<td>Alliance for Cancer Gene Therapy founded by Barbara and Edward Netter</td>
</tr>
<tr>
<td>2003</td>
<td>Human Genome project completed</td>
</tr>
<tr>
<td></td>
<td>First gene therapy drug approved for sale in China</td>
</tr>
<tr>
<td>2006</td>
<td>ACGT 5th anniversary dinner presents Lifetime Achievement Award to Dr. Judah Folkman, father of Angiogenesis</td>
</tr>
<tr>
<td>2007</td>
<td>Swim Across America launches first annual fundraiser for ACGT</td>
</tr>
<tr>
<td>2009</td>
<td>ACGT Forum in California features progress against pediatric cancers</td>
</tr>
<tr>
<td>2010</td>
<td>ACGT cited frequently in the media as a facilitator for gene therapy research</td>
</tr>
<tr>
<td></td>
<td>ACGT Scientists gather for symposium on molecular medicine</td>
</tr>
<tr>
<td>2011</td>
<td>ACGT Scientific Advisory Council member and Research Fellow, Dr. Carl June, and his team at University of Pennsylvania Abramson Cancer Center, successfully deploy a killer virus to destroy leukemia cells</td>
</tr>
<tr>
<td>2012</td>
<td>ACGT 10th anniversary dinner honoring Edward Netter</td>
</tr>
<tr>
<td>2013</td>
<td>First ACGT international Young Investigator Grant goes to Dr. Douglas Mahoney at University of Calgary, Canada</td>
</tr>
<tr>
<td></td>
<td>7th Annual Swim Across America for ACGT raises record-breaking funds</td>
</tr>
<tr>
<td></td>
<td>ACGT Immunotherapy Symposium in NYC features breakthrough research</td>
</tr>
</tbody>
</table>
Individualized drugs delivered directly to the tumor facilitate cancer cell death.

Healthy genetic medicines injected into the body train the immune system to destroy cancers and repair the damage.

The same genetic medicines that eradicate cancer will remain in the body to reject new cancers.

A vaccine will strangulate cancer cells by cutting off their blood supply and ultimately prevent cancer as well.

In the last year alone, we were able to fund two grant cycles to top-researchers in the US and Canada for innovative treatments for some of the most deadly cancers. Three grants, to three physicians at three different institutions, all pursuing a similar path using molecular medicine.

Barbara Netter
President & Co-Founder,
Alliance for Cancer Gene Therapy
All cancer is in the genes. This does not mean we are born with cancer, rather cancer is the result of a biological misfire: missing, mutated or damaged genes.

Normal cells know when to stop growing but cancer cells do not.

The immune system does not recognize cancer as a threat because it is not a foreign body.

Traditional treatments may slow the spread of the cancer or eliminate a tumor, resulting in remission, but there is still no cure.

Surgery is dependent on location, size and stage, and is an option in only 1/20 patients.

Radiation depends on location and may endanger healthy body tissue.

Chemotherapy attacks the entire body to treat the cancer.

The only way to effectively treat cancer is to target and destroy the cancer.
ACGT IS ON TRACK TO END CANCER AS WE KNOW IT.
Gene therapies are proving successful as a booster to current treatments.

Gene therapy drugs will make cancer a manageable disease like diabetes.

Gene therapy will destroy cancers permanently without damage to the body.

Gene therapy inoculations will prevent cancer.

Cancer goes the way of polio, smallpox, measles and rubella, among others.

We are optimistic. The science that once would have been considered science fiction is now reality and I have every confidence that some time soon, very soon I hope, I will report to you that molecular medicine will make cancer a manageable disease and someday, will defeat cancer entirely.

Barbara Netter
President & Co-Founder
Alliance for Cancer Gene Therapy
All ACGT research is guided by an esteemed Scientific Advisory Council and a dedicated Board of Directors.

17 trials completed or in progress based on ACGT-funded research.

$70 million additional funding secured by Research Fellows for further study based on the results of research initiated with ACGT grants.

150 publications on progress by ACGT Research Fellows.

14 ACGT Research Fellows have been cited for excellence in the field and awarded special honors for their commitments to medicine.

THOUSANDS OF PATIENTS WORLDWIDE HAVE PARTICIPATED IN GENE THERAPY TRIALS
ACGT GRANTS PAVE THE WAY TO BREAKTHROUGH RESEARCH

ACGT FUND FOR DISCOVERY: Encouraging Innovation

Up to $500,000 to Young Investigators [tenure-track assistant professors] seeking innovative cell and gene therapies for cancers of all types.

27 GRANTS | $11.8 million awarded for innovation

ACGT FUND FOR ADVANCEMENT: Stimulating Clinical Trials

Up to $1,000,000 to Senior Investigators conducting projects approaching clinical translation.

15 GRANTS | $12.4 million awarded for translational research leading to trials

ADVANCING MOLECULAR MEDICINE FOR CANCER
2013
John Bell, PhD
Institution: Ottawa Hospital Research Institute
Focus: Brain Cancer
Research: Oncolytic Viruses

2012
Douglas Mahoney, PhD
Institution: University of Calgary
Focus: Breast Cancer
Research: Tumor Specific Viruses & Bacteria

Alexander Stegh, PhD
Institution: Northwestern University
Focus: Brain Cancer
Research: Gene/Cell Mediated Therapies

Herbert J. Zeh, III, MD, FACS
Institution: University of Pittsburgh
Focus: Pancreatic Cancer
Research: Immunotherapy

2011
Hui Hu, Ph.D.
Institution: Wistar Institute
Focus: Ovarian Cancer
Research: Immunotherapy

2010
Nabil Ahmed, MD, MPH
Institution: Baylor College of Medicine
Focus: Brain Cancer
Research: Stem Cell Directed Therapy

Glenn Dranoff, MD
Institution: Dana Farber/Harvard Cancer Center
Focus: Leukemia
Research: Immunotherapy

Thomas Kipps, MD, PhD
Institution: Moores Cancer Center, University of California, San Diego
Focus: Lymphoma/Leukemia
Research: Recipient of The Swim Across America Investigator Award

Michael Z. Lin, MD, PhD
Institution: Stanford University
Focus: Brain and Breast Cancer
Research: Tumor Specific Replicating Viruses & Bacteria

2009
Steve Thorne, PhD
Institution: University of Pittsburgh
Focus: Breast & Ovarian Cancer
Research: Tumor Specific Replicating Viruses & Bacteria

George Coukos, MD, PhD
Institution: University of Pennsylvania Abramson Family Cancer Research Institute
Focus: Ovarian & Peritoneal Cancer
Research: Anti-angiogenesis Award for Cancer Gene Therapy

2008
Dr. Carl June
Institution: University of Pennsylvania Abramson Family Cancer Research Institute
Focus: Ovarian Cancer
Research: Immune-mediated Gene Therapy
Award: Recipient of The Joan Miller & Linda Bernstein Gene Therapy Ovarian Cancer Award

Antonio E. Chiocca, MD, PhD
Institution: Ohio State University Research Foundation
Focus: Brain Cancer
Research: Tumor Specific Replicating Viruses & Bacteria

Ronald Levy, MD
Institution: Stanford University
Focus: Lymphoma
Research: Immune-mediated Gene Therapy & Cancer Vaccines

Clodagh O'Shea, PhD
Institution: Salk Institute for Biological Studies
Focus: Breast Cancer
Research: Tumor Specific Replicating Viruses & Bacteria

Khalid Shah, PhD
Institution: Harvard Medical School, Massachusetts General Hospital
Focus: Brain Cancer
Research: Tumor Targeting
Award: Recipient of The Swim Across America Young Investigator Award

2007
Maciej S. Lesniak, MD
Institution: University of Chicago
Focus: Brain Cancer
Research: Tumor Targeting & Vector Development

Kah-Whye Peng, PhD
Institution: Mayo Clinic Cancer Center
Focus: Multiple Myeloma
Research: Tumor Specific Replicating Viruses & Bacteria

Eckhard Podack, MD, PhD
Institution: University of Miami Miller School of Medicine
Focus: Lung Cancer
Research: Immune-mediated Gene Therapy

Harald Sauthoff, MD
Institution: New York University
Focus: Breast/Lung Cancer
Research: Tumor Targeting & Vector Development

2006
Roberto Cattaneo, PhD
Institution: Mayo Clinic College of Medicine
Focus: Lymphoma/Leukemia
Research: Tumor Specific Replicating Viruses & Bacteria

Glenn Dranoff, MD
Institution: Dana Farber/Harvard Cancer Center
Focus: Leukemia
Research: Immunotherapy

Eckhard Podack, MD, PhD
Institution: University of Miami Miller School of Medicine
Focus: Lung Cancer
Research: Immune-mediated Gene Therapy

Harald Sauthoff, MD
Institution: New York University
Focus: Breast/Lung Cancer
Research: Tumor Targeting & Vector Development

14 ALLIANCE FOR CANCER GENE THERAPY
<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Institution</th>
<th>Focus</th>
<th>Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Biao He, PhD</td>
<td>University of Georgia</td>
<td>Breast Cancer</td>
<td>Tumor Specific Replicating Viruses &amp; Bacteria</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thomas J. Kipps, MD, PhD</td>
<td>Moores Cancer Center, University of California, San Diego</td>
<td>Lymphoma/Leukemia</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyam I. Levitsky, MD</td>
<td>Johns Hopkins University School of Medicine</td>
<td>Lymphoma/Leukemia</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Miguel Sena-Esteves, PhD</td>
<td>University of Massachusetts Medical School</td>
<td>Brain Cancer</td>
<td>Oncogenesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Koji Tamada, MD, PhD</td>
<td>University of Maryland</td>
<td>Lymphatic Systems</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Xianzheng Zhou, MD, PhD</td>
<td>New York Medical College</td>
<td>Blood, Lymphoma/Leukemia</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yiping Yang, MD, PhD</td>
<td>Duke University Medical Center</td>
<td>Lymphoma/Leukemia</td>
<td>Immunotherapy</td>
</tr>
<tr>
<td>2004</td>
<td>Chien-Fu Hung, PhD</td>
<td>Johns Hopkins University School of Medicine</td>
<td>Ovarian Cancer</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mukesh Jain, MD, FAHA</td>
<td>Case Western Reserve University</td>
<td>Metastatic Cancer</td>
<td>Anti-angiogenesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carl H. June, MD</td>
<td>University of Pennsylvania Abramson Family Cancer Research Institute</td>
<td>Lymphoma/Leukemia</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Suzie Pun, PhD</td>
<td>University of Washington</td>
<td>Metastatic Cancer</td>
<td>Anti-angiogenesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Targeted Non-Viral Delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Recipient of The Patricia Zoch Tate Gene Therapy Award</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michel Sadelain, MD, PhD</td>
<td>Memorial Sloan-Kettering Cancer Center</td>
<td>Lymphoma/Leukemia</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jian Yu, PhD</td>
<td>University of Pittsburgh School of Medicine Hillman Cancer Center</td>
<td>Lung Cancer</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td>2003</td>
<td>Laurence Cooper, MD, PhD</td>
<td>University of Texas, MD Anderson Cancer Center</td>
<td>Lymphoma/Leukemia</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Timothy Lane, PhD</td>
<td>University of California, Los Angeles</td>
<td>Breast Cancer</td>
<td>Anti-angiogenesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Todd R. Reilly, PhD</td>
<td>Johns Hopkins University [through 2006]</td>
<td>Breast Cancer</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Katherine Ryman, PhD</td>
<td>University of Pittsburgh, Center for Vaccine Research</td>
<td>Prostate Cancer</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert Vonderheide, MD, D.Phil.</td>
<td>University of Pennsylvania Abramson Family Cancer Research Institute</td>
<td>Neuroblastoma</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td>2002</td>
<td>Jeffrey S. Bartlett, PhD</td>
<td>The Research Institute at the National Children's Hospital [through 2012]</td>
<td>Ovarian Cancer</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
<tr>
<td></td>
<td>Andrew M. Davidoff, MD</td>
<td>St.Jude Children's Research Hospital</td>
<td>Neuroblastoma</td>
<td>Anti-angiogenesis</td>
</tr>
<tr>
<td></td>
<td>Thomas S. Griffith, PhD</td>
<td>University of Minnesota</td>
<td>Prostate Cancer</td>
<td>Immune-mediated Gene Therapy</td>
</tr>
</tbody>
</table>
Scientific Advisory Council members review grant proposals based on established research criteria and recommend projects for funding to the Board of Directors.

All proposed gene therapy experiments or protocols must first be approved by the research institution and by the Recombinant DNA Advisory Committee [RAC] of the National Institutes of Health [NIH] and trials must also be approved by the FDA.

**Chairman**

**Savio L.C. Woo, PhD**
Founding Chair, ACGT Scientific Advisory Council, Professor of Hematology and Oncology
Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY

---

**Council Members**

**Stuart A. Aaronson, MD**
Jane B. and Jack R. Aron Professor and Chairman Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY

**Xandra O. Breakefield, PhD**
Professor, Department of Neurology, Harvard Medical School, Geneticist, Molecular Neurogenetics Unit, Massachusetts General Hospital, Boston, MA

**Lieping Chen MD, PhD**
United Technologies Corporation Professor in Cancer Research Professor of Immunobiology, Dermatology and Medicine Director, Cancer Immunology Program, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT

**Stephen L. Eck, MD, PhD**
Vice President, Global Oncology Astellas Pharma US, Inc., Global Development, Deerfield, IL

**Joseph C. Glorioso III, PhD**
Chairman and Professor of the Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine Pittsburgh, PA

**Carl H. June, MD**
Richard W. Vague Professor in Immunotherapy, Department of Pathology and Laboratory Medicine Director Translational Research Program, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA

**Michael T. Lotze, MD**
Professor of Surgery & Bioengineering, Vice Chair Research, Department of Surgery, Director, Strategic Partnerships, University of Pittsburgh Cancer Institute, Pittsburgh, PA

**Robert L. Martuza, MD, F.A.C.S.**
Chief of Neurosurgery at Massachusetts General Hospital and William and Elizabeth Sweet, Professor of Neuroscience at Harvard Medical School, Boston, MA

**John Nemunaitis, MD**
Executive Medical Director, Mary Crowley Medical Research Center, Dallas, TX

**Drew M. Pardoll, MD, PhD**
Seraph Professor in Oncology, Co-Director, Cancer Immunology and Hematopoiesis Program Professor of Medicine, Oncology, Pathology and Molecular Biology & Genetics, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
Through highly advanced technologies, gene therapy research is focused on creating targeted delivery of therapeutic genes, engineered in the laboratory, to specific organs of patients that need repair.

**Dr. Savio Woo**
Founding Chair, ACGT Scientific Advisory Council
Professor of Hematology and Oncology
Tisch Cancer Institute, Mount Sinai School of Medicine

---

**Jack A. Roth, MD, F.A.C.S.**
Professor and Bud Johnson
Clinical Distinguished Chair, Chief,
Section of Thoracic Molecular Oncology, Professor of Molecular & Cellular Oncology, Director,
W.M. Keck Center for Innovative Cancer Therapies, The University of Texas MD Anderson Cancer Center, Houston, TX

**Stephen J. Russell, MD, PhD**
Director, Molecular Medicine Program, Consultant, Department of Hematology, Professor of Medicine, Mayo Clinic, Rochester, MN

**Michel Sadelain, MD, PhD**
Director, Center for Cell EngineeringProfessor, Molecular Pharmacology & Chemistry Program, Professor, Departments of Medicine and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY

**Thomas J. Wickham, PhD**
Senior Director, Research Merrimack Pharmaceuticals Cambridge, MA

**George D. Yancopoulos, MD, PhD**
President, Regeneron Laboratories and Chief Scientific Officer Regeneron Pharmaceuticals, Inc., Tarrytown, NY
# ACGT BOARD OF DIRECTORS

A prestigious leadership group of business, science and medical professionals establishes strategic vision, provides governance and financial oversight to the organization, and approves grant funding.

<table>
<thead>
<tr>
<th>President &amp; Co-Founder</th>
<th>In Memoriam</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Barbara Netter, MS</strong></td>
<td><strong>Edward Netter</strong></td>
</tr>
<tr>
<td>Psychotherapist</td>
<td>Founding President [2001-2011]</td>
</tr>
<tr>
<td><strong>Greenwich, CT</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Board of Directors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Daniel W. Cummings</strong></td>
</tr>
<tr>
<td>Managing Director</td>
</tr>
<tr>
<td>Harvard Management Co.</td>
</tr>
<tr>
<td>Boston, MA</td>
</tr>
<tr>
<td><strong>David M. Darst, Jr.</strong></td>
</tr>
<tr>
<td>Chief Executive Officer</td>
</tr>
<tr>
<td>RGENIX, Inc</td>
</tr>
<tr>
<td>New York, NY</td>
</tr>
<tr>
<td><strong>Peter A. Glicklich, Esq.</strong></td>
</tr>
<tr>
<td>Davies, Ward, Phillips &amp; Vineberg, LLP</td>
</tr>
<tr>
<td>New York, NY</td>
</tr>
<tr>
<td><strong>Peter C. Hearn</strong></td>
</tr>
<tr>
<td>Global Chairman</td>
</tr>
<tr>
<td>Willis Re</td>
</tr>
<tr>
<td>New York, NY</td>
</tr>
<tr>
<td><strong>Tracy Bishop Holton</strong></td>
</tr>
<tr>
<td>Attorney and Author</td>
</tr>
<tr>
<td>Greenwich, CT</td>
</tr>
<tr>
<td><strong>Jeffrey C. Keil</strong></td>
</tr>
<tr>
<td>Knight Vinke</td>
</tr>
<tr>
<td>New York, NY</td>
</tr>
<tr>
<td><em>Chairman, Executive Committee</em></td>
</tr>
<tr>
<td><strong>John L. Lahey, PhD</strong></td>
</tr>
<tr>
<td>President</td>
</tr>
<tr>
<td>Quinnipiac University</td>
</tr>
<tr>
<td>Hamden, CT</td>
</tr>
<tr>
<td><strong>Mike Moen</strong></td>
</tr>
<tr>
<td>Chief Executive Officer</td>
</tr>
<tr>
<td>Drive Power, LLC</td>
</tr>
<tr>
<td>St. Paul, MN</td>
</tr>
<tr>
<td><strong>Swan Thung, MD</strong></td>
</tr>
<tr>
<td>Director, Liver Pathology Division</td>
</tr>
<tr>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td>New York, NY</td>
</tr>
<tr>
<td><strong>Martin Winter</strong></td>
</tr>
<tr>
<td>Managing Director</td>
</tr>
<tr>
<td>Alvarez &amp; Marsal</td>
</tr>
<tr>
<td>New York, NY</td>
</tr>
<tr>
<td><strong>Eric A. Rothfeld</strong></td>
</tr>
<tr>
<td>Chairman</td>
</tr>
<tr>
<td>REI Capital, LLC</td>
</tr>
<tr>
<td>New York, NY</td>
</tr>
<tr>
<td><strong>John C. Sites, Jr.</strong></td>
</tr>
<tr>
<td>Partner</td>
</tr>
<tr>
<td>Wexford Capital, LLC</td>
</tr>
<tr>
<td>Greenwich, CT</td>
</tr>
<tr>
<td><strong>Sharon Walsted Phillips</strong></td>
</tr>
<tr>
<td>Not-for-Profit Consultant</td>
</tr>
<tr>
<td>Greenwich, CT</td>
</tr>
<tr>
<td><strong>John Reinsberg</strong></td>
</tr>
<tr>
<td>Deputy Chairman</td>
</tr>
<tr>
<td>Lazard Asset Management, LLC</td>
</tr>
<tr>
<td>New York, NY</td>
</tr>
<tr>
<td><strong>Martha Zoubek</strong></td>
</tr>
<tr>
<td>President</td>
</tr>
<tr>
<td>Wrightson-Ramsing Foundation</td>
</tr>
<tr>
<td>Greenwich, CT</td>
</tr>
</tbody>
</table>
JOIN THE ACCT PARTNERSHIP TO ADVANCE MOLECULAR MEDICINE FOR CANCER

ACGT seeks investment funding from individuals, corporations and foundations who share our commitment to the promise of better cancer care through molecular medicine.

We cannot offer you a naming opportunity, as we have no bricks and mortar, although we are proud to name a significant grant award in your honor.

If you wish, you may choose the type of cancer and/or the type of research you wish to support.

- Investor contributions are eligible for tax benefits.
- We do scrupulous due diligence so the research study you support has the greatest potential for success.
- All projects are capitalized at high award levels to facilitate meaningful results.
- Investors are partners in the process and we keep you posted on progress.
- All donated funds go directly to research as separate funding is provided to cover all administrative and fundraising expenses.

100% OF DONATIONS TO ACGT GO DIRECTLY TO RESEARCH.

Separate funding is provided to cover all administrative and fundraising costs.
“Since inception, ACGT has been at the forefront of innovative research and we are still the only charitable organization in the nation dedicated exclusively to the study of cell and gene therapies for cancer.

**Barbara Netter**
President & Co-Founder
Alliance for Cancer Gene Therapy

**THERE ARE MANY WAYS TO MAKE A DIFFERENCE**

- Donate
- Volunteer
- Host an educational program
- Organize a fundraiser
- Link us to supporters or research partners

ACGT is a 501 [c] [3] non-profit public charity founded in 2001 by Barbara and Edward Netter.

ACGT is approved by the coalition of the Better Business Bureau and the National Charities Information Bureau. ACGT is a member of the Independent Charities of America.
Do we have a cure yet? No. But great progress has been made and we have firmly positioned this organization to continue to be the driving force for progress in the future. We are confident that cancer gene therapies are moving towards a tipping point, and that someday, sooner rather than later, cancer will be treated with far greater odds for success and less toxicity to the patient.

Edward Netter
October 2010
ACGT President & Co-Founder, 2001 - 2011

The linear sequence of the letters

A [ADENINE]  
C [CYTOSINE]  
G [GUANINE]  
T [THYMINE]  

comprises the genetic code.